助手标题  
全文文献 工具书 数字 学术定义 翻译助手 学术趋势 更多
查询帮助
意见反馈
   免疫导向治疗 的翻译结果: 查询用时:0.127秒
图标索引 在分类学科中查询
所有学科
肿瘤学
妇产科学
更多类别查询

图标索引 历史查询
 

免疫导向治疗
相关语句
  immune target therapy
     [Conclusion]131I Anti c erb2 can effectively inhibit the growth of tumor cells and might be suitable to be used in immune target therapy.
     【结论】131I-Anti-c-erb2能够有效抑制肿瘤细胞的生长,适合应用于卵巢癌的免疫导向治疗
短句来源
  “免疫导向治疗”译为未确定词的双语例句
     The Experimental Study of Radioimmunotherapy on Ovarian Carcinoma Using 131I Anti c erb2 McAB
     (131)~I-Anti-c-erb2免疫导向治疗卵巢癌的实验研究
短句来源
     Objective To investigate the feasibility of targeted therapy on NPC with 188Re-BAC 5. Methods BAC 5 is a kind of monoclonal antibody to NPC.
     目的 探讨放射性核素188Re标记抗鼻咽癌 (NPC)单抗BAC5的方法及188Re -BAC5对鼻咽癌进行免疫导向治疗的可行性 .
短句来源
     A STUDY ON THE TREATMENT OF LIVER CANCER BY 131 I ANTI AFP ANTIBODY MMC “DOUBLE BOMB” IMMUNOTARGETING THERAPY
     肝癌~(131)I-抗AFP抗体-MMC“双弹头”免疫导向治疗的研究
短句来源
     The effect of immunotherapy with combined 131 I BAC 5 with CT BAC 5 is better than either of them working separately.
     CT BAC5和131I BAC5联合免疫导向治疗NPC比单项治疗效果更好。
短句来源
     ~(188)Re-labeled herceptin inhibits proliferation of breast cancer cell line SKBR-3 in vitro
     ~(188)Re-Herceptin免疫导向治疗乳腺癌的实验研究
短句来源
更多       
  相似匹配句对
     THE APPLICATION VALUE AND PROGNOSTIC SIGNIFICANCE OF THE NEW TNM STAGING SYSTEM FOR GASTRIC CANCER
     胃癌特异性免疫脂质体导向治疗的实验研究
短句来源
     In vitro and in vivo targcting therapy of inimuno-hposomes against human gastric cancer
     胃癌特异性免疫脂质体导向治疗的实验研究
短句来源
     ~(188)Re-labeled herceptin inhibits proliferation of breast cancer cell line SKBR-3 in vitro
     ~(188)Re-Herceptin免疫导向治疗乳腺癌的实验研究
短句来源
     (3) Immunogene therapy;
     (3)免疫基因治疗;
短句来源
     Boron neutron capture therapy mediated by boron - containing immunoliposomes against human gastric cancer
     胃癌免疫脂质体导向硼中子俘获治疗的研究
短句来源
查询“免疫导向治疗”译词为用户自定义的双语例句

    我想查看译文中含有:的双语例句
例句
没有找到相关例句


Production and purification of monoclonal antibodies are necessary for clinical application.A serum-free medium that can support the long-term growth and largescale propagation of hybridoma cells is a necessity.We have developed a new serumfree medium designated SCI-8910,which supports long-term growth of nine Sp2/0derived hybridoma cell lines secreting monoclonal antibodies against human small cell lung cancer(2F7,5E2,116),human hepatoma(LH-2F7),human transferrin(2C5),Fibri protein(2H4), human colonic tumor(8E9,7B10)...

Production and purification of monoclonal antibodies are necessary for clinical application.A serum-free medium that can support the long-term growth and largescale propagation of hybridoma cells is a necessity.We have developed a new serumfree medium designated SCI-8910,which supports long-term growth of nine Sp2/0derived hybridoma cell lines secreting monoclonal antibodies against human small cell lung cancer(2F7,5E2,116),human hepatoma(LH-2F7),human transferrin(2C5),Fibri protein(2H4), human colonic tumor(8E9,7B10) and human CEA antigen.The sources of materials used in preparation of SCI-8910 medium were as follow:Dulbecco's Eagle'S minimal essential medium(DMEM),F12 medium supplemented with insulin,human transferrin,slenium and other,pH7.0-7.2.The vitality of hybridoma cells in SCI-8910 was similar to or higher than that in serum-supplemented DMEM medium.By using Western blot analysis it is confirmed that the monoclonal antibody concentrated from the Supernatant of 5E2 is specific for H128 antigen.

单抗的免疫导向治疗已成为国内外肿瘤研究的热点之一。目前杂交瘤分泌单抗的来源一部分是小鼠腹水,另一部分培养于含血清的培养基内,这对单抗纯化带来困难,对免疫导向治疗也带来许多不利条件,如牛的IgG、鼠的病毒等的污染。因此,我们着手研制一种能适应于杂交瘤长期培养的无血清培基,定名为SCI-8910。现已进行了9株杂交瘤细胞的长期培养,同时用该培基在1.5L的Celliger(NBSUSA)搅拌生物反应器中长期培养鼠-鼠杂交瘤细胞2F7(分泌抗人小细胞肺癌单抗)获得成功,经检测单抗纯度达到一定要求,产品在8mg/L以上。结果提示,该无血清培基制备的MCAb用于免疫导向治疗的可行性及大规模生产的可能性。

Abstract The dual-bullets monoclonal antibody conjugates were consisted Of anti-liver cancer monoclonal antibodies (HAb18 and HAb25) conjugated with 131 I and adriamycin.The immune conjugate rate was 42.5%,the labeling rate was 49.8% and the comparative radioactivity was 6.88×104 Bq/μg (1.66μCi/μg).In the in vitro cytotoxicity study,the effect of dual-bullet MAb conjugate was markedly stronger than the mono-bullet MAb conjugate (P< 0.05). In the pilot treatment of tumor bearing mice, SPECT scanning spotted the...

Abstract The dual-bullets monoclonal antibody conjugates were consisted Of anti-liver cancer monoclonal antibodies (HAb18 and HAb25) conjugated with 131 I and adriamycin.The immune conjugate rate was 42.5%,the labeling rate was 49.8% and the comparative radioactivity was 6.88×104 Bq/μg (1.66μCi/μg).In the in vitro cytotoxicity study,the effect of dual-bullet MAb conjugate was markedly stronger than the mono-bullet MAb conjugate (P< 0.05). In the pilot treatment of tumor bearing mice, SPECT scanning spotted the tumor clearly at 168 hours with a tumor/liver ratio of 3.735±0.120, and had a much better therapeutic effect than other control groups (P<0. 05). These results demonstrated that:(1)the dual-bullets coordinate the merits of chemotherapy and radiotherapy, and thus enhance the tumor killing effect;(2)the MAb conjugates can pilot and concentrate the anti-cancer drug to the tumor target,and may some what eliminate the influesce of tumor heterogeneity on the pilot treatment.The authors believe that dual-bullets MAb conjugate pilot treatment may have opened a new prospect for comprehensive treatment of liver cancer.

肝癌"双弹头"组合单抗导向治疗的实验研究隋延仿,刘利,王文亮,刘彦仿,陈志南第四军医大学病理学教研室(西安710032)目前,肝癌免疫导向治疗在肝癌综合治疗中已发挥了重要作用,但是,已有资料显示,它的临床应用效果远不令人满意。我们在分析了这项治疗技术...

The study on radioimmunoimaging (RII) and radioimmunotherapy (RIT) for nude mice bearing human primary hepatic cancer(PHC) was preformed,using 131I-anti-AFP McAbMMC, which was a "Dual Warhead"RIT drug. After injection of 131I-anti-AFP McAb-MMC intraperitoneally(IP), selective accumulation was observed in tumor sites of nude mice bearing PHC on day 3 and the tumor growth inhibition rate was 81. 5% on day 13, higher than that in control groups.It suggests that this drug has a better affinity and stronger killing...

The study on radioimmunoimaging (RII) and radioimmunotherapy (RIT) for nude mice bearing human primary hepatic cancer(PHC) was preformed,using 131I-anti-AFP McAbMMC, which was a "Dual Warhead"RIT drug. After injection of 131I-anti-AFP McAb-MMC intraperitoneally(IP), selective accumulation was observed in tumor sites of nude mice bearing PHC on day 3 and the tumor growth inhibition rate was 81. 5% on day 13, higher than that in control groups.It suggests that this drug has a better affinity and stronger killing to human primary hepatic cancer cells.

应用双弹头免疫导向治疗药物131I-抗AFPMcAbMMC进行荷人原发性肝癌棵鼠的体内放射免疫显像(RII)及放射免疫治疗(RIT)研究。药物经腹腔给予后,第3d即能选择性的定位于肿瘤;第13d抑瘤率高达81.5%,远高于单纯131I-抗AFPMcAb组和MMC组(分别为29.6%和11.1%),提示该药物对人原发性肝癌细胞的亲和力好、杀伤力强,为其进入临床治疗提供了依据。

 
<< 更多相关文摘    
图标索引 相关查询

 


 
CNKI小工具
在英文学术搜索中查有关免疫导向治疗的内容
在知识搜索中查有关免疫导向治疗的内容
在数字搜索中查有关免疫导向治疗的内容
在概念知识元中查有关免疫导向治疗的内容
在学术趋势中查有关免疫导向治疗的内容
 
 

CNKI主页设CNKI翻译助手为主页 | 收藏CNKI翻译助手 | 广告服务 | 英文学术搜索
版权图标  2008 CNKI-中国知网
京ICP证040431号 互联网出版许可证 新出网证(京)字008号
北京市公安局海淀分局 备案号:110 1081725
版权图标 2008中国知网(cnki) 中国学术期刊(光盘版)电子杂志社